U.S. Oncology Based Molecular Diagnostics Market (2025 - 2033) Size, Share & Trends Analysis Report By Type (Breast Cancer, Lung Cancer), By Product (Instruments, Reagents), By Technology (PCR, Sequencing), By Region, And Segment Forecasts

Table of Contents

Chapter 1. U.S. Oncology Based Molecular Diagnostics Market: Methodology and Scope
                    1.1. Market Segmentation and Scope
                        1.1.1. Segment Definitions
                            1.1.1.1. Type Segment
                            1.1.1.2. Product Segment
                            1.1.1.3. Technology segment
                    1.2. Regional Scope
                    1.3. Estimates and Forecast Timeline
                    1.4. Objectives
                        1.4.1. Objective - 1
                        1.4.2. Objective - 2
                        1.4.3. Objective - 3
                    1.5. Research Methodology
                    1.6. Information Procurement
                        1.6.1. Purchased Database
                        1.6.2. GVR’s Internal Database
                        1.6.3. Secondary Sources
                        1.6.4. Primary Research
                    1.7. Information or Data Analysis
                        1.7.1. Data Analysis Models
                    1.8. Market Formulation & Validation
                    1.9. Model Details
                        1.9.1. Commodity Flow Analysis
                    1.10. List of Secondary Sources
                    1.11. List of Abbreviations
Chapter 2. U.S. Oncology Based Molecular Diagnostics Market: Executive Summary
                    2.1. Market Snapshot
                    2.2. Type and Product Snapshot
                    2.3. Technology Snapshot
                    2.4. Competitive Landscape Snapshot
Chapter 3. U.S. Oncology Based Molecular Diagnostics Market Variables, Trends, & Scope
                    3.1. Market Segmentation and Scope
                    3.2. Market Lineage Outlook
                        3.2.1. Parent Market Outlook
                        3.2.2. Related/Ancillary Market Outlook
                    3.3. Market Dynamics
                    3.4. Market Drivers Analysis
                        3.4.1. Rising Cancer Prevalence
                        3.4.2. Adoption of Precision Medicine
                        3.4.3. Advances in Molecular Testing Technologies
                    3.5. Market Restraint Analysis
                        3.5.1. High Costs of Testing and Equipment
                        3.5.2. Inconsistent Reimbursement and Regulatory Frameworks
                        3.5.3. Limited Access in Low-Resource Regions
                    3.6. Porter’s Five Forces Analysis
                    3.7. PESTLE Analysis
                    3.8. Pipeline Analysis
Chapter 4. U.S. Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis
                    4.1. U.S. Oncology Based Molecular Diagnostics Market: Type Movement Analysis
                    4.2. Breast Cancer
                        4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.3. Prostate Cancer
                        4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.4. Colorectal Cancer
                        4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.5. Cervical Cancer
                        4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.6. Liver Cancer
                        4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.7. Lung Cancer
                        4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.8. Blood Cancer
                        4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.9. Kidney Cancer
                        4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.10. Others
                        4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis
                    5.1. U.S. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
                    5.2. Instruments
                        5.2.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
                    5.3. Reagents
                        5.3.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
                    5.4. Others
                        5.4.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis
                    6.1. U.S. Oncology Based Molecular Diagnostics Market: Product Movement Analysis
                    6.2. PCR
                        6.2.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
                    6.3. In situ hybridization
                        6.3.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
                    6.4. INAAT
                        6.4.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
                    6.5. Chips and microarrays
                        6.5.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
                    6.6. Mass spectrometry
                        6.6.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
                    6.7. Sequencing
                        6.7.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
                    6.8. TMA
                        6.8.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
                    6.9. Others
                        6.9.1. market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Company Categorization
                    7.2. Strategy Mapping
                        7.2.1. New Type Launch
                        7.2.2. Partnerships
                        7.2.3. Acquisition
                        7.2.4. Collaboration
                        7.2.5. Funding
                    7.3. Key Company Market Share Analysis, 2024
                    7.4. Company Heat Map Analysis
                    7.5. Company Profiles
                        7.5.1. Abbott
                            7.5.1.1. Company Overview
                            7.5.1.2. Financial Performance
                            7.5.1.3. Type Benchmarking
                            7.5.1.4. Strategic Initiatives
                        7.5.2. Bayer AG
                            7.5.2.1. Company Overview
                            7.5.2.2. Financial Performance
                            7.5.2.3. Type Benchmarking
                            7.5.2.4. Strategic Initiatives
                        7.5.3. BD
                            7.5.3.1. Company Overview
                            7.5.3.2. Financial Performance
                            7.5.3.3. Type Benchmarking
                            7.5.3.4. Strategic Initiatives
                        7.5.4. Cepheid
                            7.5.4.1. Company Overview
                            7.5.4.2. Financial Performance
                            7.5.4.3. Type Benchmarking
                            7.5.4.4. Strategic Initiatives
                        7.5.5. Agilent technologies, inc.
                            7.5.5.1. Company Overview
                            7.5.5.2. Financial Performance
                            7.5.5.3. Type Benchmarking
                            7.5.5.4. Strategic Initiatives
                        7.5.6. Danaher
                            7.5.6.1. Company Overview
                            7.5.6.2. Financial Performance
                            7.5.6.3. Type Benchmarking
                            7.5.6.4. Strategic Initiatives
                        7.5.7. Hologic, Inc.
                            7.5.7.1. Company Overview
                            7.5.7.2. Financial Performance
                            7.5.7.3. Type Benchmarking
                            7.5.7.4. Strategic Initiatives
                        7.5.8. Qiagen
                            7.5.8.1. Company Overview
                            7.5.8.2. Financial Performance
                            7.5.8.3. Type Benchmarking
                            7.5.8.4. Strategic Initiatives
                        7.5.9. F. Hoffmann-La Roche Ltd.
                            7.5.9.1. Company Overview
                            7.5.9.2. Financial Performance
                            7.5.9.3. Type Benchmarking
                            7.5.9.4. Strategic Initiatives
                        7.5.10. Siemens
                            7.5.10.1. Company Overview
                            7.5.10.2. Financial Performance
                            7.5.10.3. Type Benchmarking
                            7.5.10.4. Strategic Initiatives
                        7.5.11. Sysmex
                            7.5.11.1. Company Overview
                            7.5.11.2. Financial Performance
                            7.5.11.3. Type Benchmarking
                            7.5.11.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 U.S. oncology based molecular diagnostics market, by Technology, 2021 - 2033 (USD Million)
Table 4 U.S. oncology based molecular diagnostics market, by Type, 2021 - 2033 (USD Million)
Table 5 U.S. oncology based molecular diagnostics market, by Product, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 U.S. Oncology based Molecular diagnostics market- Key market driver analysis
Fig. 7 U.S. Oncology based Molecular diagnostics market - Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 U.S. Oncology based Molecular diagnostics market - Porter’s analysis
Fig. 10 U.S. Oncology based Molecular diagnostics market - PESTEL analysis
Fig. 11 U.S. Oncology based Molecular diagnostics market Type outlook key takeaways
Fig. 12 U.S. Oncology based Molecular diagnostics market: Type movement analysis
Fig. 13 Breast Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 14 Prostate Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 15 Colorectal Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 16 Cervical Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 17 Liver Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 18 Lung Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 19 Blood Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 20 Kidney Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 21 Others Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 22 U.S. Oncology based Molecular diagnostics market product outlook key takeaways
Fig. 23 U.S. Oncology based Molecular diagnostics market: product movement analysis
Fig. 24 Instruments market estimates, 2021 - 2033 (USD Million)
Fig. 25 Reagents market estimates, 2021 - 2033 (USD Million)
Fig. 26 Others market estimates, 2021 - 2033 (USD Million)
Fig. 27 U.S. Oncology based Molecular diagnostics market technology outlook key takeaways
Fig. 28 U.S. Oncology based Molecular diagnostics market: technology movement analysis
Fig. 29 PCR market estimates, 2021 - 2033 (USD Million)
Fig. 30 In situ hybridization market estimates, 2021 - 2033 (USD Million)
Fig. 31 INAAT market estimates, 2021 - 2033 (USD Million)
Fig. 32 Chips and microarrays market estimates, 2021 - 2033 (USD Million)
Fig. 33 Mass spectrometry market estimates, 2021 - 2033 (USD Million)
Fig. 34 Sequencing market estimates, 2021 - 2033 (USD Million)
Fig. 35 TMA market estimates, 2021 - 2033 (USD Million)
Fig. 36 Others market estimates, 2021 - 2033 (USD Million)
Fig. 37 Strategy framework